论文部分内容阅读
目的研究肿瘤细胞减灭术联合腹腔热灌注化疗对比静脉化疗对卵巢上皮癌患者无进展生存期的差异性。方法选取2011年1月至2014年1月在本院住院的卵巢上皮癌患者138例,随机分为观察组和对照组,每组69例。一线治疗观察组采用肿瘤细胞减灭术联合腹腔热灌注化疗;对照组采用肿瘤细胞减灭术联合静脉化疗。二线治疗铂类敏感复发患者观察组10例为A组,对照组36例为B组,继续行顺铂化疗;铂类耐药复发患者观察组10例为C组,对照组22例为D组,改用紫杉醇化疗;两组复发患者的用药方式不变。结果一线治疗中,观察组患者疗效优于对照组患者,两组在肿瘤发展和生存期方面对比差异均有统计学意义(P<0.05);观察组在存活人数和生存率方面优于对照组,两组对比差异均有统计学意义(P<0.05);二线治疗中,A、B两组患者在肿瘤发展和生存期方面差异均无统计学意义(P>0.05);C组患者疗效优于D组患者,两组在肿瘤发展和生存期方面对比差异均有统计学意义(P<0.05)。结论肿瘤细胞减灭术联合腹腔热灌注化疗对卵巢上皮癌患者疗效显著,平均生存时间延长。
Objective To investigate the difference of progression-free survival of patients with epithelial ovarian cancer treated by cytoreductive surgery combined with intraperitoneal hyperthermic perfusion chemotherapy. Methods 138 patients with epithelial ovarian cancer hospitalized in our hospital from January 2011 to January 2014 were randomly divided into observation group and control group, with 69 cases in each group. The first-line treatment group was treated with cytoreductive surgery combined with intraperitoneal hyperthermic perfusion chemotherapy; the control group was treated with cytoreductive surgery combined with intravenous chemotherapy. Second-line treatment of patients with platinum-sensitive relapse observed in 10 cases of group A, 36 cases in the control group B, continue cisplatin chemotherapy; platinum-resistant relapse patients observed in 10 cases of group C, 22 cases in control group D , Switch to paclitaxel chemotherapy; two groups of patients with recurrent drug treatment unchanged. Results In the first-line treatment, the efficacy of the observation group was better than that of the control group. There was significant difference in tumor development and survival between the two groups (P <0.05). The survival rate and survival rate of the observation group were better than those of the control group (P <0.05). In the second-line treatment, there was no significant difference in tumor development and survival between A and B groups (P> 0.05). The effect of C group was superior In group D, the differences between the two groups in tumor development and survival were statistically significant (P <0.05). Conclusion Tumor cytoreductive surgery combined with intraperitoneal hyperthermic perfusion chemotherapy has a significant effect on patients with epithelial ovarian cancer and prolongs the average survival time.